2天倒计时2020年药明康德全球论坛发布完好议程

▎药明康德/报导

离别2019，转瞬咱们已来到了这个世纪的第三个十年。本年的医药健康职业，会以怎样的相貌拉开序幕，开展又是否会如您的预期？2020年1月14日下午1点，在JPM的中心希尔顿酒店，药明康德全球论坛会聚全球工业精英，与您一同预见新的十年。药明康德和药明生物董事长李革博士将做开幕致辞。

▲本次药明康德全球论坛明星聚集。长按扫描图中二维码，即可拜访论坛官方网站，了解具体议程和嘉宾简历

榜首部分：立异的当下

咱们信任，这是勇于开拓、活跃立异的十年。都说顶尖风投就像是先知，这些远见者们的慧眼透过水晶球，共享行将破土的颠覆性立异。

1:45 – 2:30

怎么拓荒簇新六合？

David Schenkein，GV（原谷歌风投）生命科学出资团队一起负责人

Antoine Papiernik，Sofinnova Partners办理合伙人

Kristiina Vuori，Sanford Burnham Prebys医学研讨所所长

胡正国，药明康德联席首席履行官

掌管：Eric Elenko，PureTech Health首席立异官

2:30 – 2:50

对话Howard “Skip” Burris，美国临床肿瘤学会（ASCO）新任主席；Sarah Cannon临床运营总裁兼首席医学官

掌管：Fred Hausheer，药明康德全球首席医学官兼WuXi Oncology负责人

第二部分：聚光灯下的基因与细胞疗法

咱们信任，这是归于基因和细胞疗法的十年。本年的这一范畴，多条爆款新闻的缔造者将齐聚一堂，回顾历史的经历与经历，畅谈未来的机会和方向。

2:50 – 3:20

细胞疗法：何处是前方？

Richard Klausner，Lyell Immunopharma创始人兼首席履行官

Patrick Hwu，MD安德森癌症中心肿瘤医学部负责人

掌管：Karen Bernstein，BioCentury一起创始人兼董事长

3:20 – 3:50

开释基因疗法的潜力

James Wilson，宾夕法尼亚大学医学院教授；基因疗法项目负责人

Tachi Yamada，Frazier Healthcare Partners出资合伙人

掌管：John Carroll，Endpoints News编缉兼创始人

第三部分：向治好疾病冲刺

咱们信任，这是向治好疾病的方针冲刺的十年。传统的小分子药物和生物药将持续应战一个又一个未竟难题，新颖的靶点和效果机制也将不断走向老练。

3:50 – 4:10

对话刘如谦（David Liu），哈佛大学教授；霍华德·休斯医学研讨所（HHMI）研讨员；Merkin研讨所主任；Broad研讨所教员副主任

掌管：陈智胜，药明生物首席履行官

4:10 – 4:55

按部就班仍是日新月异？

Paul-Peter Tak，Kintai Therapeutics总裁兼首席履行官

Steve Paul，Karuna Therapeutics董事长兼首席履行官

Samantha Du，再鼎医药董事长兼首席履行官

Lalo Flores，Century Therapeutics首席履行官

掌管：杨青，药明康德履行副总裁，首席商务官

第四部分：预见2030

咱们信任，这是拥抱新式技能，从头界说医疗的十年。实在世界依据，医疗大数据，长途数字医疗，癌症液体活检……很多人都只是听过这些术语的姓名，却不知道它们终究有何含义。在未来的十年，这些技能会以怎样的速率改动医疗的相貌？

4:55 – 5:15

对话Hans Bishop，GRAIL首席履行官

掌管：Melinda Richter，强生立异JLABS全球负责人

5:15 – 6:00

技能怎么界说未来医疗健康？

Jason Coloma，Maze Therapeutics总裁兼首席履行官

Zavain Dar，Lux Capital合伙人

Carolyn Magill，Aetion首席履行官

John Halamka，Mayo Clinic Platform总裁

王磊，阿斯利康全球履行副总裁，世界事务及我国总裁

掌管：Kenneth Kaitin，塔夫茨大学医学院教授；塔夫茨药物开发研讨中心主任

咱们更信任，这全部的全部，含义在于为全球的病患带来更多打破，这也正是咱们“Advancing Breakthroughs for Patients”主题的由来。

现在，已有超越3000位职业资深人士注册参与论坛。咱们等待思想的沟通能碰撞出火花，照亮职业前行的路途。咱们也等待在一系列重磅打破之下，全球病患能提前用得上，也用得起更多好药新药。

2020年1月14日，在JPM的中心，咱们不见不散！

Announcing the Full Agenda of WuXi Global Forum 2020

Now in its eighth year, WuXi Global Forum 2020 will continue to bring together thousands of leaders to promote new thinking on a global stage as we strive to provide transformative solutions for patients.

In order to accommodate the growing number of attendees,the WuXi Global Forum 2020 will take place on Jan 14 at the Hilton San Francisco Union Square and feature an expanded program from 1:00 – 7:00 PM PST.

This invitation-only and complimentary event is brought to you by WuXi AppTec, BayHelix, BioCentury, Biocom, BioWorld, ChinaBio, Children's Tumor Foundation, CLSA, Endpoints News, Fiercebiotech, Informa, MassBio, MBC BioLabs and UK BioIndustry Association.

AGENDA

1:00 – 1:30

REGISTRATION and NETWORKING

1:30 – 1:35

WELCOME

Hui Cai, Forum Chair, VP and Head of Content Division, WuXi AppTec

1:35 – 1:45

OPENING REMAKRS

Ge Li, Chairman, WuXi AppTec and WuXi Biologics

SESSION I STATE OF INNOVATION

1:45 – 2:30

Are We Breaking New Ground?

David Schenkein, General Partner, GV

Antoine Papiernik, Managing Partner, Sofinnova Partners

Kristiina Vuori, President, Sanford Burnham Prebys Medical Discovery Institute

Edward Hu, Co-CEO, WuXi AppTec

Moderated byEric Elenko, Chief Innovation Officer, PureTech Health

2:30 – 2:50

A Dialogue withHoward “Skip” Burris, President, ASCO; President of Clinical Operations and CMO, Sarah Cannon

Moderated byFred Hausheer, Global Chief Medical Officer and Head of WuXi Oncology, WuXi AppTec

SESSION II SPOTLIGHT ON CELL AND GENE THERAPIES

2:50 – 3:20

Cell Therapies: Where Are We Heading?

Richard Klausner, Founder and CEO, Lyell Immunopharma

Patrick Hwu, Head, Division of Cancer Medicine, MD Anderson Cancer Center

Moderated byKaren Bernstein, Co-Founder and Chairman, BioCentury

3:20 – 3:50

Delivering the Promise of Gene Therapies

James Wilson, Professor of Medicine and Pediatrics of Department of Medicine and Director of Gene Therapy Program, University of Pennsylvania

Tachi Yamada, Venture Partner, Frazier Healthcare Partners

Moderated byJohn Carroll, Editor and Founder, Endpoints News

SESSION III RACE TO THE CURE

3:50 – 4:10

A Dialogue withDavid Liu, Director of the Merkin Institute and Vice-Chair of the Faculty, Broad Institute; Professor of Harvard University and HHMI

Moderated byChris Chen, CEO, WuXi Biologics

4:10 – 4:55

Incremental or Transformative?

Paul-Peter Tak, President and CEO, Kintai Therapeutics

Steve Paul, Chairman and CEO, Karuna Therapeutics

Samantha Du, Chairman and CEO, Zai Lab

Lalo Flores, CEO, Century Therapeutics

Moderated bySteve Yang, EVP and CBO, WuXi AppTec

SESSION IV INNOVATION 2030

4:55 – 5:15

A Dialogue withHans Bishop, CEO, GRAIL

Moderated byMelinda Richter, Global Head, Johnson & Johnson Innovation, JLABS

5:15 – 6:00

How is Technology Shaping the Future of Healthcare?

Jason Coloma, President and CEO, Maze Therapeutics

Zavain Dar, Partner, Lux Capital

Carolyn Magill, CEO, Aetion

John Halamka, President, Mayo Clinic Platform

Leon Wang, Executive VP International and China President, AstraZeneca

Moderated byKenneth Kaitin, Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

6:00 – 6:10

CLOSING REMARKS

Steve Bates, CEO, UK BioIndustry Association

6:10 – 7:00

RECEPTION